Posters

Early commercial outcomes using mitomycin C with hydrogel shape-changing corneal inlay with and without concurrent LASIK

Poster Details

First Author: J.Whitman USA

Co Author(s):                        

Abstract Details

Purpose:

To assess clinical outcomes after implantation of the Raindrop�Â�® Near Vision Inlay (ReVision Optics, Inc., Lake Forest, CA, USA) using Mitomycin C (MMC).

Setting:

Key-Whitman Eye Center11442 N Central ExpresswayDallas, Texas 75243USA

Methods:

33 presbyopes were implanted with the Raindrop Inlay in the non-dominant eye under a femtosecond laser flap. A mixture of emmetropes with inlay only (Inlay, n=26) as well as ametropes with inlay and concurrent LASIK (LASIK, n=7) were treated with 0.02% MMC to the stomal bed and flap for 20 seconds. Patients assessment at 1 day, 1 week, 1 month, and 3 months postop included visual acuities and corneal clarity.

Results:

The mean preop MRSEs were 0.4 D for inlay only and -1.63 D for inlay LASIK. At 1 day, the average UDVAs were 20/66 (inlay) and 20/50 (LASIK). Distance acuity improves or stabilizes from 1W to 3M (Inlay: 20/53, 20/42, 20/34; LASIK: 20/41, 20/41, 20/47). Average UNVAs were 20/37 (inlay) and 20/41 (LASIK) at 1 week and improves to 20/28 (Inlay) and 20/36 (LASIK) at 3M. Two patients experienced early haze, both treated with steroids. Longer term data will be reported at the congress.

Conclusions:

In my commercial practice, the Raindrop Near Vision Inlay provided good monocular near visual acuity out to 3 months. Distance vision was decreased early on due to post-surgical healing but improved over time. Complications were minimal in this group of patients.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented